CJC-1295 with and without DAC: distinct materials
CJC-1295 with and without DAC: distinct materials: Compare identities, model types and limitations. These are research comparisons, not treatment rankings.
CJC-1295 with DAC
The DAC form has an albumin-binding extension and differs from no-DAC material. The cited long-acting clinical study concerns DAC. This store does not list DAC as an interchangeable variant.
CJC-1295 no DAC
A no-DAC GHRH analogue commonly described as modified GRF 1-29. The peptide is studied through the growth-hormone-releasing hormone pathway. It does not contain the DAC form’s albumin-binding extension. Frequently cited CJC-1295 clinical literature concerns the DAC molecule. Those pharmacokinetic findings are not direct evidence for the no-DAC material. The two forms must not share half-life or efficacy assumptions. Human outcome evidence for this exact material is limited. The Standard lists only the no-DAC version.
Comparison limits
A shared category does not prove equal effects, compatibility or suitability. Verify the exact sequence, formulation and batch. Do not substitute a related molecule or ingredient finding for direct evidence.
Sources & scope
Long-acting CJC-1295 study (2006)
Compare the catalogue identifiers
| Material | Listed vial amounts | Interpretation |
|---|---|---|
| CJC-1295 with DAC | Consult the exact lot documentation for purity, expiry and storage information. | A different material or form. Compare the evidence and documents below; amounts do not establish equivalence. |
| CJC-1295 no DAC | 2 mg / 5 mg / 10 mg | A different material or form. Compare the evidence and documents below; amounts do not establish equivalence. |
For in-vitro laboratory research only. Not for human or veterinary use.